Influence of apolipoprotein E phenotype on changes in plasma levels of low-density lipoprotein-cholesterol and apolipoprotein B due to the effects of simvastatin

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 8, Issue 6, 1998, Pages 358-364

  Kobayashi, T ^a   Homma, Y ^a   Handa, S ^b   Nakamura, H ^c  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Apo E phenotype; HMG CoA reductase inhibitor; LDL receptor activity; Plasma apolipoproteins; Plasma lipids

Indexed keywords

EID: 0001136857     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Havel RJ, Kane JP (1995) Introduction: structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1841-1851
2. Goldstein JL, Hobbs HH, Brown MS (1995) Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, McGraw-Hill, New York, pp 1981-2030
3. Goldstein JL, Brown MS (1984) Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 25: 1450-1460
4. Weintraub MS, Eisenberg S, Breslow JL (1987) Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 80: 1571-1577
5. Kesaniemi YA, Ehnholm C, Miettinen TA (1987) Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 80: 578-581
6. Mahley RW, Rall SC (1995) Type III hyperlipoproteinemia (Dysbeta-lipoproteinemia): The role of apoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, McGraw-Hill, New York, pp 1841-1980
7. Gylling H, Miettinen TA (1992) Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apo E phenotypes. J Lipid Res 33: 1361-1371
8. Tikkanen MJ, Huttunen JK, Ehnholm C, Dietine P (1990) Apolipoprotein E4 hemozygosity predispose to serum cholesterol elevation during high fat diet. Arteriosclerosis 10: 285-288
9. Miettinen TA, Gylling H, Vanhanen H, Ollus A (1992) Cholesterol absorption, elimination, and synthesis related to LDL kinetics during fat intake in men with different apoprotein E phenotype. Arterioscl Thromb 12: 1044-1052
10. Jones PJH, Main BI, Frohlich JJ (1993) Response of cholesterol synthesis to cholesterol feeding in men with different apolipoprotein E phenotypes. Metabolism 42: 1065-1071
11. Weisgraber KH, Innerarity TL, Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257: 2518-2521
12. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer Jr. HB (1986) Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78: 815-821
13. Demart T, Bedford D, Packard CJ, Shepherd J (1991) Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 88: 1490-1501
14. Scandinavian Simvastatin Survival Study Group (1994) Rondomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S) Lancet 344: 1383-1409
15. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, Mckillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307
16. Sacks FM, Pfeffer NA, Moye LA, Roulean JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wan CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009
17. O'Malley JP, Illingworth DR (1990) The influence of apoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 39: 150-154
18. Knijff PD, Stalenhoef AFH, Mol MJTM, Leuven JAG, Smith J, Erkelen DW, Schouten J, Frants RR, Havekes LM (1990) Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 83: 89-97
19. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J (1993) The response to lovastastin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42: 895-901
20. Ordovas JM, Lopez-Miranda J, Peter-Jimenez F, Rodriguez C, Park J-S, Cole T, Schaefer EJ (1995) Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy. Athreosclerosis 113: 157-166
21. Homma Y, Kobayashi T, Yamaguchi H, Ozawa H, Sakane H, Nakamura H (1997) Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 129: 241-248
22. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
23. Kataoka S, Paichi N, Howard BV (1994) Simplified isoelectric focusing immunoblotting determination of apoprotein E phenotype. Clin Chem 40: 11-13
24. Ranganathan S, Hattori H, Kashyap ML (1995) A rapid flow cytometric assay for low-density lipoprotein receptors in human peripheral blood mononuclear cells. J Lab Clin Med 125: 479-486
25. Shen MM, Krauss RM, Lindgren FT, Forte TM (1981) Heterogeneity of serum low density lipoprotein in normal human subjects. J Lipid Res 22: 236-244
26. Campos H, Blijlevens E, McNamara JR, Ordoas JM, Posner BM, Wilson PW, Castelli WP, Schaefer EJ (1992) LDL particle size distribution. Results from the Framingham offspring study. Arterioscl Thromb 12: 1410-1419
27. Gaw A, Packard JP, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J (1993) Effects of simvastatin on apo B metabolism and LDL subfraction distribution. Arterioscl Thromb 13: 170-189
28. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H (1995) Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesterol ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 114: 223-234
29. Savolainen MJ, Rantala M, Kervinen K, Jarvi L, Suvanto K, Rantala T, Kesaniemi YA (1991) Magnitude of dietary effects on plasma cholesterol concentration: role of sex and apolipoprotein E phenotype. Atherosclerosis 86: 145-152
30. Cobb MM, Teitlebaum H, Risch N, Jekel J, Ostfeld A (1992) Influence of dietary fat, apolipoprotein E phenotype, and sex on plasma lipoprotein levels. Circulation 868: 49-57
31. Zambon D, Ros E, Casals C, Sanllehy C, Bertomen T, Campero I (1995) Effect of apolipoprotein E polymorphism on the serum lipid response to a hypolipidemic diet rich in monounsaturated fatty acid in patients with hypercholesterolemia and combined hyperlipidemia. Am J Clin Nutr 61: 141-148
32. Eto M, Watanabe K, Chonan N, Ishii K (1988) Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 72: 123-128
33. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1-21
34. Chao Y-S, Kroon PA, Yamin TT, Thompson GM, Alberts AW (1983) Regulation of hepatic receptor-dependent degradation of LDL by mevilonin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Biochim Biophys Acta 754: 134-141
35. Malmendier CL, Lontie J-F, Delcroix C, Magot T (1989) Effects of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 80: 101-109
36. Reihner E, Pudling M, Stahlbery D, Berylund L, Ewerth S, Bjorkhem I, Einersson K, Angelin B (1990) Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 323: 224-228
37. Metsunaga A, Sasaki J, Takada Y, Hidaka K, Arakawa K (1991) Effects of simvastatin on receptor-mediated metabolism of low-density lipoprotein in guinea pigs. Atherosclerosis 90: 31-37